1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Vaishali Pharma Limited

Vaishali Pharma Limited

VAISHALI.NS
Vaishali Pharma LimitedIN flagNational Stock Exchange of India
7.43
INR
+0.12
- -
796.44MMarket Cap

Total Valuation

Vaishali Pharma Limited carries a market capitalization of 796.44M, placing it among publicly traded companies globally. Its enterprise value stands at 1.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap796.44M
Enterprise Value1.68B

Share Statistics

Vaishali Pharma Limited currently has 130.46M shares outstanding.

Shares Outstanding130.46M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Vaishali Pharma Limited trades at a trailing price-to-earnings ratio of 192.69. The price-to-sales ratio is 1.61, and the price-to-book ratio stands at 3.77.

PE Ratio192.69
PS Ratio1.61
PB Ratio3.77
P/TBV Ratio2.46
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Vaishali Pharma Limited trades at an EV/EBITDA multiple of 28.49 and an EV/FCF ratio of 121.97. The EV/Sales ratio of 1.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 28.49 provides insight into valuation relative to core operating earnings.

EV / Sales1.72
EV / EBITDA28.49
EV / EBIT28.49
EV / FCF121.97

Financial Position

Vaishali Pharma Limited maintains a current ratio of 2.61, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.98, indicating elevated leverage, while an interest coverage ratio of 2.85 demonstrates limited ability to service its debt obligations.

Current Ratio2.61
Quick Ratio0.04
Debt / Equity18.98
Debt / EBITDA2.09
Interest Coverage2.85

Financial Efficiency

Vaishali Pharma Limited posts a return on equity of 2.42 and a return on invested capital of 5.89.

Return on Equity (ROE)2.42
Return on Assets (ROA)0.86
Return on Invested Capital (ROIC)5.89
Return on Capital Employed (ROCE)4.71
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover33.02

Taxes

Over the trailing twelve months, Vaishali Pharma Limited has paid 4.08M in income taxes, reflecting an effective tax rate of 33.32.

Income Tax4.08M
Effective Tax Rate33.32

Stock Price Statistics

Vaishali Pharma Limited's stock has declined approximately -37.08721% over the past 52 weeks. The 50-day moving average sits at 7.31, while the 200-day moving average is 8.17.

Beta (5Y)N/A
52-Week Price Change-37.08721%
50-Day Moving Average7.31
200-Day Moving Average8.17
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Vaishali Pharma Limited generated 978.82M in revenue and converted that into 8.17M in net income, yielding earnings per share of 0.06. EBITDA reached 59.00M, while operating income came in at 59.00M.

Revenue978.82M
Gross Profit122.07M
Operating Income59.00M
Pretax Income12.26M
Net Income8.17M
EBITDA59.00M
EBIT59.00M
Earnings Per Share (EPS)0.06

Balance Sheet

Vaishali Pharma Limited holds 17.11M in cash and equivalents against 123.18M in total debt, resulting in a net debt position of 99.49M. Total book value stands at 418.21M, with working capital of 644.31M providing operational flexibility.

Cash & Cash Equivalents17.11M
Total Debt123.18M
Net Debt99.49M
Equity (Book Value)418.21M
Book Value Per Share3.34
Working Capital644.31M

Margins

Vaishali Pharma Limited operates with a gross margin of 12.47, reflecting its pricing power and cost economics. The operating margin of 6.03 and net profit margin of 0.84 provide insight into operational efficiency.

Gross Margin12.47
Operating Margin6.03
Pretax Margin1.25
Profit Margin0.84
EBITDA Margin6.03

Stock Splits

Vaishali Pharma Limited's most recent stock split took place on October 15, 2024 with a 1:5 split ratio.

Last Split Date10/15/2024
Split Ratio1:5

Scores

Vaishali Pharma Limited posts an Altman Z-Score of 4.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.09